List of bibliographic references
Number of relevant bibliographic references: 6.
| Ident. | Authors (with country if any) | Title |
|---|
| 000377 (2017) |
Giuseppe Saglio [Italie] ; Philipp Le Coutre [Allemagne] ; Jorge Cortes [États-Unis] ; Ji Mayer [République tchèque] ; Philip Rowlings [Australie] ; François-Xavier Mahon [France] ; Glenn Kroog [États-Unis] ; Kyna Gooden [États-Unis] ; Milayna Subar [États-Unis] ; Neil P. Shah [États-Unis] | Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios |
| 000729 (2016) |
Jeffrey H. Lipton [Canada] ; Charles Chuah [Singapour] ; Agnès Guerci-Bresler [France] ; Gianantonio Rosti [Italie] ; David Simpson [Nouvelle-Zélande] ; Sarit Assouline [Canada] ; Gabriel Etienne [France] ; Franck E. Nicolini [France] ; Philipp Le Coutre [Allemagne] ; Richard E. Clark [Royaume-Uni] ; Leif Stenke [Suède] ; David Andorsky [États-Unis] ; Vivian Oehler [États-Unis] ; Stephanie Lustgarten [États-Unis] ; Victor M. Rivera [États-Unis] ; Timothy Clackson [États-Unis] ; Frank G. Haluska [États-Unis] ; Michele Baccarani [Italie] ; Jorge E. Cortes [États-Unis] ; François Guilhot [France] ; Andreas Hochhaus [Allemagne] ; Timothy Hughes [Australie] ; Hagop M. Kantarjian [États-Unis] ; Neil P. Shah [États-Unis] ; Moshe Talpaz [États-Unis] ; Michael W. Deininger [États-Unis] | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. |
| 000974 (2016) |
Michael W. Deininger [États-Unis] ; J. Graeme Hodgson [États-Unis] ; Neil P. Shah [États-Unis] ; Jorge E. Cortes [États-Unis] ; Dong-Wook Kim [Corée du Sud] ; Franck E. Nicolini [France] ; Moshe Talpaz [États-Unis] ; Michele Baccarani [Italie] ; Martin C. Müller [Allemagne] ; Jin Li [États-Unis] ; Wendy T. Parker [Australie] ; Stephanie Lustgarten [États-Unis] ; Tim Clackson [États-Unis] ; Frank G. Haluska [États-Unis] ; Francois Guilhot [France] ; Hagop M. Kantarjian [États-Unis] ; Simona Soverini [Italie] ; Andreas Hochhaus [Allemagne] ; Timothy P. Hughes [Australie] ; Victor M. Rivera [États-Unis] ; Susan Branford [Australie] | Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients |
| 000F88 (2014) |
Simona Soverini [Italie] ; Susan Branford [Australie] ; Franck E. Nicolini [France] ; Moshe Talpaz [États-Unis] ; Michael W N. Deininger [États-Unis] ; Giovanni Martinelli [Italie] ; Martin C. Müller [Allemagne] ; Jerald P. Radich [États-Unis] ; Neil P. Shah [États-Unis] | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. |
| 002216 (2008) |
Neil P. Shah [États-Unis, Corée du Sud, France, Brésil, Argentine, Mexique, Russie, Australie, Allemagne] ; Hagop M. Kantarjian ; Dong-Wook Kim ; Delphine Rea ; Pedro E. Dorlhiac-Llacer ; Jorge H. Milone ; Jorge Vela-Ojeda ; Richard T. Silver ; H. Jean Khoury ; Aude Charbonnier ; Nina Khoroshko ; Ronald L. Paquette ; Michael Deininger ; Robert H. Collins ; Irma Otero ; Timothy Hughes ; Eric Bleickardt ; Lewis Strauss ; Stephen Francis ; Andreas Hochhaus | Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia |
| 002412 (2007) |
Jacob M. Rowe [États-Unis] ; Andreas Hochhaus [Allemagne] ; Hagop M. Kantarjian [États-Unis] ; Michele Baccarani [Italie] ; Jeffrey H. Lipton [Canada] ; Jane F. Apperley [Royaume-Uni] ; Brian J. Druker [États-Unis] ; Thierry Facon [France] ; Stuart L. Goldberg [États-Unis] ; Francisco Cervantes [Espagne] ; Dietger Niederwieser [Allemagne] ; Richard T. Silver [États-Unis] ; Richard M. Stone [États-Unis] ; Timothy P. Hughes [Australie] ; Martin C. Muller [Allemagne] ; Rana Ezzeddine [États-Unis] ; Athena M. Countouriotis [États-Unis] ; Neil P. Shah [États-Unis] | Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Commentary |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Humans |
| 3 | Fusion Proteins, bcr-abl (genetics) |
| 3 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy) |
| 2 | Adult |
| 2 | Aged |
| 2 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 2 | Antineoplastic agent |
| 2 | DNA Mutational Analysis (methods) |
| 2 | Drug Resistance, Neoplasm (genetics) |
| 2 | Enzyme inhibitor |
| 2 | Female |
| 2 | Imatinib |
| 2 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics) |
| 2 | Male |
| 2 | Middle Aged |
| 2 | Protein Kinase Inhibitors (therapeutic use) |
| 2 | Protein-tyrosine kinase |
| 1 | Adolescent |
| 1 | Aged, 80 and over |
| 1 | Amino Acid Substitution |
| 1 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Cancerology |
| 1 | Cardiovascular Diseases (chemically induced) |
| 1 | Cardiovascular Diseases (epidemiology) |
| 1 | Chemotherapy, Adjuvant |
| 1 | Chronic myelocytic leukemia |
| 1 | Chronic myelogenous leukemia |
| 1 | Clinical Trials as Topic (methods) |
| 1 | Clinical Trials as Topic (statistics & numerical data) |
| 1 | Cytogenetics |
| 1 | DNA Mutational Analysis (trends) |
| 1 | Daily dose |
| 1 | Dasatinib |
| 1 | Dasatinib (adverse effects) |
| 1 | Disease-Free Survival |
| 1 | Drug-Related Side Effects and Adverse Reactions (classification) |
| 1 | Drug-Related Side Effects and Adverse Reactions (pathology) |
| 1 | Forecasting |
| 1 | High-Throughput Nucleotide Sequencing |
| 1 | Imatinib Mesylate (administration & dosage) |
| 1 | Imatinib Mesylate (adverse effects) |
| 1 | Imidazoles (administration & dosage) |
| 1 | Imidazoles (adverse effects) |
| 1 | Imidazoles (therapeutic use) |
| 1 | Incidence |
| 1 | Ischemia (chemically induced) |
| 1 | Ischemia (epidemiology) |
| 1 | Kaplan-Meier Estimate |
| 1 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive (pathology) |
| 1 | Leukemia, Myeloid, Chronic-Phase (drug therapy) |
| 1 | Leukemia, Myeloid, Chronic-Phase (genetics) |
| 1 | Mutation |
| 1 | Mutation (physiology) |
| 1 | Neoadjuvant Therapy |
| 1 | Outcome Assessment (Health Care) (methods) |
| 1 | Outcome Assessment (Health Care) (statistics & numerical data) |
| 1 | Philadelphia Chromosome (drug effects) |
| 1 | Practice Guidelines as Topic |
| 1 | Prognosis |
| 1 | Prostatic Neoplasms (drug therapy) |
| 1 | Protein Kinase Inhibitors (adverse effects) |
| 1 | Protein Kinase Inhibitors (pharmacology) |
| 1 | Pyridazines (administration & dosage) |
| 1 | Pyridazines (adverse effects) |
| 1 | Pyridazines (therapeutic use) |
| 1 | Resistance |
| 1 | Targeting |
| 1 | Treatment |
| 1 | Treatment Outcome |
| 1 | Treatment efficiency |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Neil P. Shah"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Neil P. Shah" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Neil P. Shah
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
